Your browser doesn't support javascript.
loading
A kinase-cGAS cascade to synthesize a therapeutic STING activator.
McIntosh, John A; Liu, Zhijian; Andresen, Brian M; Marzijarani, Nastaran Salehi; Moore, Jeffrey C; Marshall, Nicholas M; Borra-Garske, Margie; Obligacion, Jennifer V; Fier, Patrick S; Peng, Feng; Forstater, Jacob H; Winston, Matthew S; An, Chihui; Chang, Wonsuk; Lim, Jongwon; Huffman, Mark A; Miller, Steven P; Tsay, Fuh-Rong; Altman, Michael D; Lesburg, Charles A; Steinhuebel, Dietrich; Trotter, B Wesley; Cumming, Jared N; Northrup, Alan; Bu, Xiaodong; Mann, Benjamin F; Biba, Mirlinda; Hiraga, Kaori; Murphy, Grant S; Kolev, Joshua N; Makarewicz, Amanda; Pan, Weilan; Farasat, Iman; Bade, Rachel S; Stone, Kevin; Duan, Da; Alvizo, Oscar; Adpressa, Donovan; Guetschow, Erik; Hoyt, Erik; Regalado, Erik L; Castro, Steve; Rivera, Nelo; Smith, Joseph P; Wang, Fengqiang; Crespo, Alejandro; Verma, Deeptak; Axnanda, Stephanus; Dance, Zachary E X; Devine, Paul N.
Afiliação
  • McIntosh JA; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA. john.mcintosh1@merck.com.
  • Liu Z; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA. liuquani@gmail.com.
  • Andresen BM; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA. brian.m.andresen@gmail.com.
  • Marzijarani NS; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Moore JC; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Marshall NM; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Borra-Garske M; Codexis, Inc., Redwood City, CA, USA.
  • Obligacion JV; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Fier PS; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Peng F; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Forstater JH; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Winston MS; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • An C; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Chang W; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Lim J; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Huffman MA; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Miller SP; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Tsay FR; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Altman MD; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Lesburg CA; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Steinhuebel D; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Trotter BW; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Cumming JN; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Northrup A; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Bu X; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Mann BF; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Biba M; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Hiraga K; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Murphy GS; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Kolev JN; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Makarewicz A; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Pan W; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Farasat I; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Bade RS; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Stone K; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Duan D; Codexis, Inc., Redwood City, CA, USA.
  • Alvizo O; Codexis, Inc., Redwood City, CA, USA.
  • Adpressa D; Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Guetschow E; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Hoyt E; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Regalado EL; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Castro S; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Rivera N; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Smith JP; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Wang F; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Crespo A; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Verma D; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Axnanda S; Process Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Dance ZEX; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Devine PN; Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, USA.
Nature ; 603(7901): 439-444, 2022 03.
Article em En | MEDLINE | ID: mdl-35296845
ABSTRACT
The introduction of molecular complexity in an atom- and step-efficient manner remains an outstanding goal in modern synthetic chemistry. Artificial biosynthetic pathways are uniquely able to address this challenge by using enzymes to carry out multiple synthetic steps simultaneously or in a one-pot sequence1-3. Conducting biosynthesis ex vivo further broadens its applicability by avoiding cross-talk with cellular metabolism and enabling the redesign of key biosynthetic pathways through the use of non-natural cofactors and synthetic reagents4,5. Here we describe the discovery and construction of an enzymatic cascade to MK-1454, a highly potent stimulator of interferon genes (STING) activator under study as an immuno-oncology therapeutic6,7 (ClinicalTrials.gov study NCT04220866 ). From two non-natural nucleotide monothiophosphates, MK-1454 is assembled diastereoselectively in a one-pot cascade, in which two thiotriphosphate nucleotides are simultaneously generated biocatalytically, followed by coupling and cyclization catalysed by an engineered animal cyclic guanosine-adenosine synthase (cGAS). For the thiotriphosphate synthesis, three kinase enzymes were engineered to develop a non-natural cofactor recycling system in which one thiotriphosphate serves as a cofactor in its own synthesis. This study demonstrates the substantial capacity that currently exists to use biosynthetic approaches to discover and manufacture complex, non-natural molecules.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guanosina / Nucleotidiltransferases Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guanosina / Nucleotidiltransferases Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
...